Lopinavir/ritonavir treatment in HIV antiretroviral‐experienced patients: evaluation of risk factors for liver enzyme elevationPaola Meraviglia, A. Cargnel, Marco Bongiovanni et al.|HIV Medicine|2004Cited by 61
Hypothyroidism in HIV‐Infected Patients Who Have or Have Not Received HAARTTiziana Quirino, Marco Bongiovanni, Elena Ricci et al.|Clinical Infectious Diseases|2004Cited by 36
Predictive factors of lopinavir/ritonavir discontinuation for drug-related toxicity: results from a cohort of 416 multi-experienced HIV-infected individualsMarco Bongiovanni, Antonella d’Arminio Monforte, Paola Cicconi et al.|International Journal of Antimicrobial Agents|2005Cited by 33
Virological Success of Lopinavir/Ritonavir Salvage Regimen is Affected by an Increasing Number of Lopinavir/Ritonavir-Related MutationsMarco Bongiovanni, Antonella d’Arminio Monforte, Teresa Bini et al.|Antiviral Therapy|2003Cited by 25
Predictive Factors of Hyperlipidemia in HIV-Infected Subjects Receiving Lopinavir/RitonavirMarco Bongiovanni, Antonella d’Arminio Monforte, Teresa Bini et al.|AIDS Research and Human Retroviruses|2006Cited by 17